Allan Lawrie

Professor Allan Lawrie is Chair of Pulmonary Vascular Diseases at the National Heart & Lung Institute, Faculty of Medicine, Imperial College London. He previously served as Professor of Translational Cardiopulmonary Science at the University of Sheffield (2018–2022), where he established a translational research program in Pulmonary Hypertension and co-founded the Donald Heath Centre for Pulmonary Hypertension Research. His academic journey includes a BSc (Hons) from Edinburgh Napier University and a PhD from the University of Sheffield.

Research Focus

Lawrie's research deciphers molecular mechanisms in pulmonary hypertension, emphasizing translational outcomes like novel therapies (e.g., an OPG-targeting antibody) and biomarkers. His work spans:

• Osteoprotegerin (OPG)/TRAIL axis pathology
• Cardiopulmonary disease mechanisms
• Therapeutic antibody development
• Clinical biomarker innovation

Awards & Leadership

• Senior Fellowships: British Heart Foundation, Medical Research Council
• Prestigious Society Fellowships: American Heart Association, Pulmonary Vascular Research Institute
• Key Roles: Co-Director of BHF Doctoral Training Programme; Chair of NHLI Research Committee; Trustee of Scleroderma & Raynaud's UK
• Grant Leadership: Secured MRC DPFS award for antibody therapeutics

Academic Contributions

Lawrie co-founded PH Therapeutics Ltd to advance pulmonary hypertension treatments and mentors through Imperial's BHF training initiative. He champions open research as NHLI's Open Research Lead.